Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2025 03:27 ET | Source: Nxera Pharma

Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapiesHTL0039732, was found to be...
October 18, 2025 03:00 ET | Source: AdvanCell

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer...
October 17, 2025 10:30 ET | Source: Artios Pharma

Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical...
October 17, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Completes First In Human Dose Escalation for TT125-802 and Presents Solid Tumor Monotherapy Results at ESMO 2025

Monotherapy shows deep and durable responses in NSCLC and a best-in-class safety profile without thrombocytopeniaCompletion of monotherapy dose escalation part of the study will be followed by the...
October 16, 2025 07:00 ET | Source: BPGbio

BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025

BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to...
October 12, 2025 18:05 ET | Source: AdvanCell

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025 Results from the Phase 1b dose escalation of the...
July 25, 2025 09:00 ET | Source: Evaxion

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year...
February 26, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Gastrointestinal Cancer Research: Comprehensive Conference Coverage for Competitive Insights | DelveInsight

New York, USA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Gastrointestinal Cancer Research: Comprehensive Conference Coverage for Competitive Insights | DelveInsight A case study on how one of the leading...
February 19, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Oncology Conference Coverage — Stay Ahead in the Oncology Domain with Real-time Coverage from AACR, ESMO, ASCO, ASH, EHA, and Others | DelveInsight

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oncology Conference Coverage — Stay Ahead in the Oncology Domain with Real-time Coverage from AACR, ESMO, ASCO, ASH, EHA, and Others | DelveInsight ...
December 02, 2024 08:00 ET | Source: Evaxion Biotech

Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress

COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present...